enlicitide decanoate
Sponsor Merck & CO INC. · listed as MRK
enlicitide decanoate is a drug asset sponsored by Merck & CO INC., listed as MRK. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Nov 26, 2027 (day precision, medium confidence), tied to trial NCT07821944. That trial is in Phase 3 and currently not yet recruiting, studying Hyperlipidemia. It appears across 5 tracked trials in the CSA sample.
Next catalyst
Trial & sponsor
Trials for enlicitide decanoate in the CSA sample
| Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|
| NCT07216482 | Phase 3 | Active, not recruiting | 2026-08-03 | Experimental | Merck Sharp & Dohme LLC | Hyperlipidemia |
| NCT07821944 catalyst | Phase 3 | Not yet recruiting | 2027-11-26 | Experimental | Merck Sharp & Dohme LLC | Hyperlipidemia; Hypercholesterolemia |
| NCT06492291 | Phase 3 | Active, not recruiting | 2028-10-13 | Experimental | Merck Sharp & Dohme LLC | Hypercholesterolemia |
| NCT06008756 | Phase 3 | Active, not recruiting | 2029-11-29 | Experimental | Merck Sharp & Dohme LLC | Arteriosclerosis; Hypercholesterolaemia |
| NCT07058077 | Phase 2/3 | Recruiting | 2033-12-04 | Experimental | Merck Sharp & Dohme LLC | Heterozygous Familial Hypercholesterolemia (HeFH) |
Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 → More MRK catalysts